Class / Patent application number | Description | Number of patent applications / Date published |
424196110 | Conjugate or complex includes virus or componenet thereof | 80 |
20080260773 | Saccharide Conjugate Vaccines - The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising T cell epitopes from two or more pathogens conjugated to saccharide antigen. The invention also provides a multivalent conjugate comprising two or more antigenically distinct saccharide antigens conjugated to the same carrier protein molecule, wherein the carrier protein comprises T cell epitopes from two or more pathogens. Further compositions comprise one or more of said monovalent conjugates and one or more of said multivalent conjugates. The invention further provides methods for making said compositions and uses for said compositions. | 10-23-2008 |
20080260774 | Alpha-galactosyl ceramide analogs and their use as immunotherapies - The present disclosure relates to synthetic alpha-galactosyl ceramide (α-GalCer) analogs, and their use as immunotherapies. In one aspect, a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: | 10-23-2008 |
20080274134 | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex - This invention provides methods for eliciting an immune response in a subject comprising administering to the subject as part of a regimen (i) more than one dose of a nucleic acid prime, and (ii) more than one dose of a protein boost composition, wherein each dose of the nucleic acid prime is administered to the subject at a first predefined interval and each dose of the protein boost composition is administered to the subject at a second predefined interval, and wherein the protein boost composition comprises a prophylactically or therapeutically effective dose of (a) a trimeric HIV-1 gp140 protein complex, or (b) a superparamagnetic particle and a trimeric HIV-1 gp140 protein complex so affixed thereto as to permit recognition of the complex by a subject's immune system. The invention also provides methods for prophylactically or therapeutically treating HIV-1 infection in a subject. The invention further provides uses of a nucleic acid prime and a protein boost composition for the manufacture of separate coadministerable medicaments to be administered to a subject. | 11-06-2008 |
20090035326 | COMPOSITIONS WITH ANTIGENS ADSORBED TO CALCIUM PHOSPHATE - Calcium phosphate is used as an adjuvant, with a high degree of antigen adsorption to the adjuvant. The invention is particularly useful for adjuvanting conjugated capsular saccharide antigens. Buffers, such as phosphate or histidine buffers, can advantageously be used in combination with the calcium phosphate, and compositions may have a pH in the range of 5.5 to 7.5. | 02-05-2009 |
20090092633 | Polyamino acid for use as adjuvant - Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle. | 04-09-2009 |
20090098155 | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease - The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant. | 04-16-2009 |
20090104223 | Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations - The invention relates to a method for obtaining aggregated antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune response and to the chemical structures resulting from the application of said method, to the formulations obtained from such structures and their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoket inside the yeast by changing incubation conditions. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens can be introduced, wherein synergism between said components is found with respect to the immunogenicity of the response obtained. The preparation may also contain stabilizers and preservatives. The resulting antigenic structures can be used in the pharmaceutical industry as preventive or therapeutic vaccine formulation both for human and veterinary use and as part of diagnostic system. | 04-23-2009 |
20090175896 | CAT Allergen Conjugates and Uses Thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens. | 07-09-2009 |
20090202583 | Rhinovirus Vaccines - The present invention relates generally to peptide vaccines. More specifically, the present invention relates to vaccines against rhinoviruses and other related and non-related pathogenic animal viruses. In addition, the present invention relates generally to methods of designing and producing vaccines against viruses and, in certain embodiments, against rhinoviruses and other pathogenic viruses. | 08-13-2009 |
20090202584 | TREATMENT OF EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES - The present invention relates to a vaccine for the treatment or prevention of an EBV-associated disease in a subject, wherein said vaccine comprises a synthetic polypeptide comprising a plurality of different segments of at least one parent EBV polypeptide, and wherein the segments are linked together in a different relationship relative to their linkage in the at least one parent EBV polypeptide. | 08-13-2009 |
20090202585 | TAT-BASED TOLEROGEN COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - A Tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (HIV) trans-activator of transcription (Tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided. | 08-13-2009 |
20090208526 | Combination vaccines with low dose of hib conjugate - Provided herein are combination vaccines comprising antigens for protecting a subject against at least diphtheria, tetanus, pertussis and Hib, wherein: (a) the antigen for protecting against Hib is a conjugate of a Hib capsular saccharide; (b) the concentration of the Hib conjugate in the vaccine is <15 μg/ml; and (c) the Hib conjugate has never been lyophilised. | 08-20-2009 |
20090317422 | USE OF PPD FOR THE ADJUVANTATION OF A NUCLEIC ACID VACCINE - The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines. | 12-24-2009 |
20100034847 | Multiple vaccination including Serogroup C Meningococcus - Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular | 02-11-2010 |
20100040645 | IN VIVO CTL ELICITATION BY HEAT SHOCK PROTEIN FUSION PROTEINS MAPS TO A DISCRETE DOMAIN AND IS CD4+ T CELL-INDEPENDENT - The present invention relates to a method of inducing a CD8 | 02-18-2010 |
20100040646 | Split-Core-Particles for the Presentation of Foreign Molecules, Especially for Vaccine Applications, and Method for their Production - Disclosed are split-core carrier substances which, as separate polypeptides, have the core N domain and the core C domain of the core protein of a hepatitis B virus and at least one foreign molecule against which an immune response is to be induced. According to the invention, the foreign molecule, especially the heterologous foreign amino acid sequence, is fused to the C terminus of the core N domain or to the N terminus of the core C domain and the core protein can form capsid-like particles. The invention also relates to the associated production method. | 02-18-2010 |
20100047271 | VACCINE COMPOSITIONS - The present invention relates generally to an immunogenic complex comprising a charged organic carrier and a charged antigen and, more particularly, a negatively charged organic carrier and a positively charged antigen, wherein the charged antigen is a polyprotein of Hepatitis C Virus (HCV), particularly the core protein of HCV, or a fragment thereof, or a fusion protein comprising the polyprotein or a fragment thereof. The complexes of the present invention are useful, inter alia, in vaccine compositions as therapeutic and/or prophylactic agents for facilitating the induction of immune responses, and in particular a cytotoxic T-lymphocyte response, in the treatment of a disease condition which results from an HCV infection. | 02-25-2010 |
20100074918 | VACCINE - The present invention relates to the field of vaccines and in particular to combination vaccines and co-administration schedules. The present inventor discloses that overuse of CRM in paediatric vaccines can result in bystander immune interference to certain antigens and provide solutions to this problem. | 03-25-2010 |
20100092508 | Molecular Antigen Arrays - The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses. | 04-15-2010 |
20100111995 | Antigen conjugates and uses thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen of the invention, wherein said antigen of the invention is CCR5 of the invention, gastrin of the invention, CXCR4 of the invention, CETP of the invention or C5a of the invention. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of diseases in which the antigen of the invention mediates, or contributes to the condition, particularly for the treatment of AIDS, gastrointestinal cancers, coronary heart diseases or inflammatory diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. | 05-06-2010 |
20100129395 | Hapten-carrier conjugates and uses thereof - The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction. | 05-27-2010 |
20100221281 | HIGH MOLECULAR WEIGHT POLYSACCHARIDE THAT BINDS AND INHIBITS VIRUS - This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses. | 09-02-2010 |
20100285055 | Activation of natural killer (NK) cells and methods of use - The present invention relates to filovirus VLPs and their use in activating innate immunity, specifically natural killer cells, and in enhancing an immune response to an antigen in an animal. | 11-11-2010 |
20100316665 | PAPAYA MOSAIC VIRUS-BASED VACCINES AGAINST SALMONELLA TYPHI AND OTHER ENTEROBACTERIAL PATHOGENS - An antigen-presenting system (APS) comprising one or more enterobacterial antigens in combination with a papaya mosaic virus (PapMV) or a virus like particle (VLP) derived from papaya mosaic virus is provided. The PapMV or VLP included in the APS is capable of potentiating an immune response against said one or more enterobacterial antigens. The APS can be used, for example, as a vaccine against enterobacterial disease, such as typhoid fever. The one or more antigens comprised by the APS can be conjugated to a coat protein of the PapMV or PapMV VLP, or they may be non-conjugated (i.e. separate from the PapMV or PapMV VLP), or the APS can comprise both conjugated and non-conjugated antigens. Conjugation can be, for example, by genetic fusion with the coat protein, or binding via covalent, non-covalent or affinity means. | 12-16-2010 |
20100322962 | ANTIGEN-NOROVIRUS P-DOMAIN MONOMERS AND DIMERS, ANTIGEN-NOROVIRUS P-PARTICLE MOLECULES, AND METHODS FOR THEIR MAKING AND USE - A substituted Norovirus capsid protein monomer, having only the P-domain and called an antigen-Norovirus P-domain monomer, includes a foreign antigen inserted into one or more of three surface loops present on each P-domain monomer by molecular cloning. The antigen-P-domain monomer can assemble spontaneously into an octahedral form, called an antigen-Norovirus P-particle, that is composed of 24 copies of the antigen-P-domain monomer. Each substituted P-domain monomer will contain one to three copies of the foreign antigen, for a total of 24-72 antigen copies on each antigen-P-particle. The antigen-P-particle is useful in methods for diagnosing, immunizing and treating individuals infected with a foreign virus, for example Rotavirus, and can serve as a carrier for presentation of foreign antigens for development of novel vaccines against many infectious and non-infectious diseases. The substituted Norovirus P-particles can be readily produced in | 12-23-2010 |
20100330115 | Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody - The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates. | 12-30-2010 |
20110014226 | HIGH THROUGHPUT PROTEIN INTERACTION ASSAY - A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen-antibody interactions of interest. In one embodiment, the antigen is a pathogen-derived antigen and the antibody decreases or inhibits virulence of the pathogen when bound to the antigen (e.g., a neutralizing antibody, antibody with serum bactericidal activity, etc.). In another embodiment, the antigen is a self-antigen (autoantigen) and the antibody is an autoantibody that is known to be associated with a pathological condition (e.g., autoimmune disorder). Compounds that bind to the antigen or antibody disrupt binding can be used as therapeutics to decrease or inhibit the autoimmune disorder. | 01-20-2011 |
20110027306 | TC-83-Derived Alphavirus Vectors, Particles and Methods - The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs. | 02-03-2011 |
20110076304 | ADAPTER MOLECULE FOR THE DELIVERY OF ADENOVIRUS VECTORS - The invention relates to an adapter protein comprising a coxackievirus and adenovirus receptor (CAR) region and a human CD40 ligand and to the uses thereof for promoting adenoviral transduction of dendritic cells while at the same time promoting maturation of the DCs. The invention also relates to pharmaceutical compositions comprising said adapter protein and an adenovirus encoding an antigen and the uses thereof in a method for eliciting an immune response against the antigen encoded in said adenovirus as well as to antigen-loaded dendritic cells obtained the adaptor protein and an adenovirus and to the uses thereof in a method of eliciting an immune response against the antigen encoded in the adenovirus. | 03-31-2011 |
20110110972 | STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS - Compositions and methods for treating immune cells and activating immune responses are disclosed. The compositions comprise one or more optically active chiral cationic lipids. | 05-12-2011 |
20110171248 | SYNTHETIC VIRUS-LIKE PARTICLES CONJUGATED TO HUMAN PAPILLOMAVIRUS CAPSID PEPTIDES FOR USE AS VACCINES - Disclosed are compositions and related methods that involve a synthetic nanocarrier that includes at least one peptide obtained from Human papillomavirus L1 or L2 capsid protein; wherein the peptide is coupled to an external surface of the synthetic nanocarrier. | 07-14-2011 |
20110206724 | HEPATITIS VIRUS CORE PROTEINS AS VACCINE PLATFORMS AND METHODS OF USE THEREOF - The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations. | 08-25-2011 |
20110206725 | METHOD FOR PURIFYING PROTEIN COMPLEXES - The present invention provides a method for the purification of complexes comprising a stress protein complexed to a peptide or peptide fragment, from a source mixture, typically a cell lysate. The improved method of the invention provides for protein complexes to be purified using ion exchange based methods, without the need to use chemicals such as chaotropes and ampholytes. The purified complexes can be used as the immunogenic determinant in vaccine compositions for the treatment or prevention of infectious diseases or cancerous conditions. | 08-25-2011 |
20110212124 | Vaccine Composition - The present invention relates to new, advantageous DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided. | 09-01-2011 |
20110311573 | Method for Preparing Recombinant Antigen Complex Using Rotavirus Nanoparticle - Disclosed are a construct for expressing a rotavirus antigen complex loaded with a heterologous virus epitope, a vaccine composition containing the rotavirus antigen complex, a virus-like particle of rotavirus containing the rotavirus antigen complex, and a vaccine composition containing the virus-like particle of rotavirus. According to the present disclosure, an antigen complex containing a rotavirus antigen as well as a heterologous virus epitope and a virus-like particle of rotavirus containing the antigen complex can be produced in large scale at low cost. Thus, the present disclosure may be applied for research and development of novel complex vaccines for rotavirus and heterologous virus. | 12-22-2011 |
20110311574 | MULTIPLE VACCINATION INCLUDING SEROGROUP C MENINGOCOCCUS - Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular | 12-22-2011 |
20120009212 | CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR STIMULATING IMMUNE RESPONSE - Templated conjugates created from naturally-occurring protein sequences found in pathogens, such as viruses, are disclosed. The sequences are “templated” into a consensus coiled-coil sequence in order to form a two-stranded antigen suitable for immunization of a subject. | 01-12-2012 |
20120064110 | SYNTHETIC NANOCARRIER VACCINES COMPRISING PEPTIDES OBTAINED OR DERIVED FROM HUMAN INFLUENZA A VIRUS HEMAGGLUTININ - This invention relates to compositions and methods that can be used immunize a subject against influenza. Generally, the compositions and methods include peptides obtained or derived from human influenza A virus hemagglutinin. | 03-15-2012 |
20120107345 | MANUFACTURE OF VACCINES THAT CONTAIN BOTH HEPATITIS B VIRUS SURFACE ANTIGENS AND SURFACTANT - When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification. | 05-03-2012 |
20120171240 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS - The invention provides conjugates comprising an immune co-stimulatory polypeptide and an antigen or infectious agent. The conjugates are useful for generating or enhancing an immune response against the antigen or infectious agent. The invention also provides immune cells modified with a conjugate that are useful for generating or enhancing an immune response to an antigen or infectious agent. The invention also provides immunostimulatory moieties comprising an immune co-stimulatory polypeptide that are useful for stimulating an immune response. The invention also provides immunotherapy methods and methods of treating or preventing infections. | 07-05-2012 |
20120183573 | INTRACELLULAR VIRAL VECTOR DELIVERY METHOD EMPLOYING IRON ION/VIRAL VECTOR COMPOSITE - The present invention relates to an intracellular viral vector delivery method employing an iron ion/viral vector composite. The iron ion/viral vector composite according to the present invention is not dependent on the expression of CAR and so improves the efficiency of delivery of viral vectors and gene expression in cells of diverse types, and has an outstanding virus-neutralizing antibody escape performance, exhibits little cytotoxicity and is outstandingly stable even when subjected to iron ion processing at low concentration, and hence can be used to advantage in recombinant viral vaccine compositions. | 07-19-2012 |
20120207780 | Vaccine Composition - A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide of | 08-16-2012 |
20120294888 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY - Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen. | 11-22-2012 |
20120301499 | Packaging of Immunostimulatory Substances into Virus-Like Particles: Method of Preparation and Use - The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases. | 11-29-2012 |
20120321659 | HBV CORE ANTIGEN PARTICLES WITH MULTIPLE IMMUNOGENIC COMPONENTS ATTACHED VIA PEPTIDE LIGANDS - This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them. | 12-20-2012 |
20130004534 | INACTIVATION OF REVERSE TRANSCRIPTASES BY AZIDO-DIARYLPYRIMIDINES - Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided. | 01-03-2013 |
20130011431 | Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. In one embodiment, the construct containing the Aβ1-6 peptide consists of a virus-like particle (VLP) of the RNA bacteriophage Qβ chemically coupled to said Aβ1-6 peptide. | 01-10-2013 |
20130028930 | Albumin Derivatives and Variants - The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides. | 01-31-2013 |
20130084306 | VACCINES COMPRISING CHOLESTEROL AND CPG AS SOLE ADJUVANT-CARRIER MOLECULES - Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders. | 04-04-2013 |
20130101617 | ENV TRIMER IMMUNOGENS - Embodiments of the present invention are drawn to pure forms of human or simian immunodeficiency virus trimeric gp120/gp41 Env protein (Env trimers) and methods for making them. These embodiments address the need for an authentic immunogen lacking uncleaved gp160 Env protein and/or other forms of Env, such as gp41 “stumps” dissociated from gp120, which interfere with neutralizing antibody production in a vaccinated subject. | 04-25-2013 |
20130142821 | Hapten-Carrier Conjugates and Uses Thereof - The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction. | 06-06-2013 |
20130171186 | BROAD SPECTRUM INFLUENZA A NEUTRALIZING VACCINES AND D-PEPTIDIC COMPOUNDS, AND METHODS FOR MAKING AND USING THE SAME - GB1 peptidic compounds that specifically bind to a hemagglutinin target protein, and libraries that include the same, as well as methods of making and using the same, are provided. Also provided are methods and compositions for making and using the compounds. Also provided are hemagglutinin mimics and fragments and methods of using the same, including methods of screening for GB1 peptidic compounds and methods of using conjugates the mimics as influenza A vaccines. Aspects of the invention include methods of screening libraries of L-peptidic compounds for specific binding to a D-peptidic hemagglutinin target protein. Once a L-peptidic compound has been identified that specifically binds to the D-peptidic hemagglutinin target protein, the D-enantiomer of the selected L-peptidic compound may be produced. In some embodiments, the D-enantiomer of the selected L-peptidic compound binds to, and in some instances, neutralizes influenza virus particles. | 07-04-2013 |
20130236491 | SPHERICAL NANO AND MICROPARTICLES DERIVED FROM PLANT VIRUSES FOR THE DISPLAY OF FOREIGN PROTEINS OR EPITOPES - A novel type of particle platform for application in biotechnology is provided by the present invention. Said platforms comprise RNA-free particles generated by thermal denaturation and structural remodeling of helical plant viruses. Tobamovir-uses and, in particular, tobacco mosaic virus (TMV) coat protein (CP) subunits, denatured, at high temperatures are specifically self-assembled by two-stage assembly into the spherical particles (SPs) of similar shape and varying size including nanoparticles (SNPs) with a diameter up to 100-150 nm and spherical microparticles (SMPs) with a diameter up to 800 nm and more. The size of said SPs depends on the virus concentration used and, therefore can be controlled. Said SPs are biologically safe, highly stable and highly immunogenic. Said SNPs and SMPs are structurally distinct from viruses presently known. They are unique, having no protein nano-particle analogs in the nature. Said particles can be produced by the native virus and also by different forms of viral CP lacking RNA. The SPs can be generated by thermal denaturation and structural remodeling of different helical plant viruses belonging to genera | 09-12-2013 |
20130251744 | VIRUS LIKE PARTICLE COMPOSITION - The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof. | 09-26-2013 |
20130295131 | GENERATION OF ANTIGENIC VIRUS-LIKE PARTICLES THROUGH PROTEIN-PROTEIN LINKAGES - We have generated virus-like particles (VLPs) that can display other proteins through covalent protein-protein linkages mediated by the ‘Dock and Lock’ interaction between the | 11-07-2013 |
20130302366 | Conformationally Specific Viral Immunogens - The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine. | 11-14-2013 |
20130315949 | Molecular Antigen Array - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 11-28-2013 |
20130337005 | NANOPARTICLES FOR PROVIDING IMMUNE RESPONSES AGAINST INFECTIOUS AGENTS - Nanoparticles for providing immune responses for the treatment or prophylaxis of infection by infectious agents such as viruses, parasites, bacteria, prions and fungi are described which comprises a core including metal and/or semiconductor atoms, wherein the core is covalently linked to a plurality of ligands, the ligands including a carbohydrate residue capable of stimulating an innate immune response, a T cell helper peptide and a danger signal. This platform may then be adapted by including one or more further ligands capable of producing a specific response to a target infectious agent. | 12-19-2013 |
20140079730 | COMPOSITION COMPRISING VLP AND AMYLOID BETA PEPTIDE - The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A□-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia. in particular dementia of the A | 03-20-2014 |
20140112950 | COMBINATION VACCINES WITH LOWER DOSES OF ANTIGEN AND/OR ADJUVANT - Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant. | 04-24-2014 |
20140120131 | COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS - Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle. | 05-01-2014 |
20140141036 | In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus Like Particles - The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens. | 05-22-2014 |
20140141037 | RSV F PREFUSION TRIMERS - Complexes that contain RSV F ectodomain polypeptides and methods for making the complexes are disclosed. The RSV F ectodomain polypeptides can be in the prefusion form. | 05-22-2014 |
20140205628 | HIGH MOLECULAR WEIGHT POLYSACCHARIDE THAT BINDS AND INHIBITS VIRUS - This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses. | 07-24-2014 |
20140205629 | TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS - The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs. | 07-24-2014 |
20140322262 | METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 10-30-2014 |
20140370049 | METHOD FOR FORMULATING A VACCINE CONTAINING AT LEAST TWO ANTIGENS CAPABLE OF ADSORBING ONTO ALUMINIUM OXYHYDROXIDE - The subject matter of the invention is a method for preparing a vaccine composition comprising at least aluminium oxyhydroxide (AlOOH), and at least the hepatitis B surface antigen and the | 12-18-2014 |
20150024002 | ALPHAVIRUS VECTORS FOR RESPIRATORY PATHOGEN VACCINES - Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to | 01-22-2015 |
20150037367 | Methods and Compositions Of Protein Antigens For The Diagnosis And Treatment of Herpes Simplex Viruses Type 1 and 2 - Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter. | 02-05-2015 |
20150050317 | Means for Eliciting an Immune Response and a Method Therefor - A means to elicit a cytotoxic immune response as a result of injecting antigen encoding expression constructs. Minimalistic expression constructs are used that comprise a promoter, a coding sequence and a terminator, and hairpin-shaped oligonucleotides on their ends, to the loop of which cationic peptides are covalently attached. These peptide-coupled expression constructs lead to a cell mediated response type after intradermal injection. The use of a DNA expression construct operable in eucaryotic cells for making a vaccine for intradermal injection to elicit a type 1 cell mediated immune mediated immune response is described. | 02-19-2015 |
20150056244 | Antigens and Vaccines Directed Against Human Enteroviruses - The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection. | 02-26-2015 |
20150093410 | Stimulation of An Immune Response By Cationic Lipids - The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens. | 04-02-2015 |
20150297739 | DEVELOPMENT OF A HIGHLY EFFICIENT SECOND GENERATION NICOTINE-CONJUGATE VACCINE TO TREAT NICOTINE ADDICTION - The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate. | 10-22-2015 |
20150320855 | IN VIVO ACTIVATION OF ANTIGEN PRESENTING CELLS FOR ENHANCEMENT OF IMMUNE RESPONSES INDUCED BY VIRUS-LIKE PARTICLES - The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens. | 11-12-2015 |
20150352218 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM - 1H-Imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed. | 12-10-2015 |
20160068533 | IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES - The invention provides compounds of formula I: | 03-10-2016 |
20160101167 | Composition of Organic Compounds - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. | 04-14-2016 |
20160158344 | Methods And Compositions of Protein Antigens For The Diagnosis And Treatment of Herpes Simplex Viruses Type 1 And 2 - Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter. | 06-09-2016 |
20160175431 | Vaccine Composition | 06-23-2016 |
20160193327 | MUCOSAL VACCINE COMPOSITION | 07-07-2016 |